Mark Scott, Ph.D.

Mark Scott, Ph.D.

Executive Director, Chemistry, Manufacturing & Controls

EDUCATION
B.Sc.E., Engineering Chemistry, Queen's University
M.Sc.Eng., Chemical Engineering, Queen's University
Ph.D., Organic Chemistry, University of Toronto
Post-Doc, Organic Chemistry, Princeton University

PREVIOUS EXPERIENCE
Merck
Gilead Sciences

Mark’s FlareTx characteristics: Scientific excellence. Helping deliver new treatments for patients with unmet medical needs. 

With more than a decade in drug discovery and development, Mark is focused on supporting pipeline development activities through the development of processes and their controls to enable the consistent delivery of high quality drug substance and drug product materials for patients.

In his time in industry, Mark has contributed to the discovery and development of numerous pre-clinical, clinical, and commercial compounds including niraparib, voxilaprevir, and more recently firsocostat for the treatment of NASH (non-alcoholic steatohepatitis).

Outside of work, Mark is an avid gardener who enjoys trips to the mountains and numerous outdoor activities with his wife and two children.

WHAT MAKES YOU EXCITED TO ‘BRING IT’ EVERY DAY AT WORK?

The needs of our patients.

WHAT SPARKED YOU TO JOIN FLARETX?

The high level of scientific thought by the team and their creative approaches to solve tough problems.

 

This links to an external website.

Continue